Improving Inflammation Resolution to Mitigate Acquired Bone Marrow Failure
改善炎症消退以减轻获得性骨髓衰竭
基本信息
- 批准号:10595109
- 负责人:
- 金额:$ 51.58万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-01 至 2027-05-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAlternative TherapiesAplastic AnemiaAutoimmune DiseasesBehaviorBiologicalBiological AssayBloodBone MarrowBone Marrow TransplantationBone marrow failureCD47 geneCell Surface ReceptorsCellsChronicDataDiseaseEffectivenessElderlyEquilibriumFailureGPR18 receptorGenerationsHealthHematopoieticHematopoietic Stem Cell TransplantationHematopoietic stem cellsHost DefenseHumanImmuneImmunosuppressionImpairmentInfectionInflammationInflammation ProcessInflammatoryInflammatory ResponseKineticsKnowledgeLeukotrienesLifeMacrophageMarrowMediatingMediatorMissionMolecularMusNatural regenerationOmega-3 Fatty AcidsOrganismOutcomePTPNS1 genePathogenesisPathway interactionsPatientsPhysiologicalPredispositionProductionProstaglandinsRecoveryRefractoryResolutionRoleSeriesTestingTherapeuticTherapeutic immunosuppressionTimeTransgenic MiceTransplantationUnited States National Institutes of HealthWorkacquired bone marrow failureagedbone marrow failure syndromeburden of illnesscell injuryhematopoietic stem cell self-renewalhuman diseaseimprovedinsightlipid mediatormortalitymouse modelnew therapeutic targetnovelnovel strategiesnovel therapeuticsolder patientpreventprogramsreceptorreceptor expressionreparative processstandard of carestem cell functionsurvival outcometransplantation therapy
项目摘要
Improving Inflammation Resolution to Mitigate Acquired Bone Marrow Failure
Bone marrow failure is the devastating collapse of blood production, and current treatments are
inadequate. First line therapies include immunosuppressive therapies, and when feasible, bone marrow
transplantation. These therapies are often efficacious in the short-term, especially for young patients,
however they are much less effective in older patients. Immune suppression is not well tolerated,
especially in the elderly, and carries increased susceptibility to infection. Therefore, alternative
therapies are needed. It is well established that bone marrow failure is associated with non-resolving
inflammation. The resolution of inflammation requires the balance between pro-inflammatory
leukotrienes or prostaglandins and w3-derived specialized pro-resolving mediators (SPMs), like
resolvins. Using a mouse model of acquired severe aplastic anemia (SAA) that mirrors key features of
human disease, we established a role for impaired inflammation resolution programs in disease
pathogenesis. Our preliminary work demonstrates the effectiveness of SPMs in ameliorating SAA. The
rationale for the proposed work is that rather than blunting inflammatory responses, promoting
resolution and reparative processes may be an ideal therapeutic strategy for bone marrow failure. The
proposed studies will address a fundamental gap in our understanding of the physiologically relevant
process of inflammation resolution in the bone marrow. We propose three integrated, but independent,
Aims to: (1) address mechanisms of impaired resolution, (2) determine the impact of SPMs in the
marrow in SAA, and (3) evaluate the effect of SPMs on function of hematopoietic stem cells.
The proposed work will support a novel approach to treat BMF without the use of immune suppression,
representing an important departure from the current standard of care. We believe these studies will be
impactful therapeutic options for BMF patients, particularly older patients where IST has failed, and
wherein host defenses are already weakened. At the same time, the proposed studies may provide
new mechanistic insight relevant to other diseases characterized by prolonged and non-resolved
inflammation, and thus will have broad impact to human health.
改善炎症消退以减轻获得性骨髓衰竭
骨髓衰竭是血液生产的毁灭性崩溃,目前的治疗方法是
不足一线治疗包括免疫抑制治疗,可行时,骨髓
移植这些疗法通常在短期内有效,特别是对年轻患者,
然而,它们对老年患者的效果要差得多。免疫抑制的耐受性不好,
尤其是在老年人中,并且增加了感染的易感性。因此,替代
需要治疗。骨髓衰竭与非消退性
炎症炎症的解决需要促炎和炎症反应之间的平衡。
白细胞三烯或白藜芦醇和W3衍生的特化促消退介质(SPM),如
消退素。使用获得性重型再生障碍性贫血(SAA)的小鼠模型,
人类疾病,我们建立了受损的炎症解决方案在疾病中的作用,
发病机制我们的初步工作证明了SPM在改善SAA方面的有效性。的
提出这项工作的理由是,
解决和修复过程可能是骨髓衰竭的理想治疗策略。的
拟议的研究将解决我们对生理相关性的理解中的一个根本性的空白。
骨髓中炎症消退的过程。我们提出三个一体化,但独立,
目的是:(1)解决受损分辨率的机制,(2)确定SPM在
(3)观察SPM对SAA骨髓造血干细胞功能的影响。
拟议的工作将支持一种新的方法来治疗BMF,而不使用免疫抑制,
这与目前的护理标准有很大的不同。我们相信这些研究将
为BMF患者提供有效的治疗选择,特别是IST失败的老年患者,
宿主的防御已经被削弱了与此同时,拟议的研究可能提供
与其他疾病相关的新机制见解,其特征是长期和未解决
炎症,因此将对人类健康产生广泛影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KATHERINE C. MACNAMARA其他文献
KATHERINE C. MACNAMARA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KATHERINE C. MACNAMARA', 18)}}的其他基金
Hematopoietic Stem Cell Dysfunction and Regeneration in Severe Infection
严重感染时造血干细胞功能障碍和再生
- 批准号:
10371061 - 财政年份:2019
- 资助金额:
$ 51.58万 - 项目类别:
Hematopoietic Stem Cell Dysfunction and Regeneration in Severe Infection
严重感染时造血干细胞功能障碍和再生
- 批准号:
9902469 - 财政年份:2019
- 资助金额:
$ 51.58万 - 项目类别:
Hematopoietic Stem Cell Dysfunction and Regeneration in Severe Infection
严重感染时造血干细胞功能障碍和再生
- 批准号:
10598451 - 财政年份:2019
- 资助金额:
$ 51.58万 - 项目类别:
Interferon gamma Regulation of CD4 T Cell Responses in Tuberculosis
干扰素 γ 对结核病中 CD4 T 细胞反应的调节
- 批准号:
7666156 - 财政年份:2008
- 资助金额:
$ 51.58万 - 项目类别:
Interferon gamma Regulation of CD4 T Cell Responses in Tuberculosis
干扰素 γ 对结核病中 CD4 T 细胞反应的调节
- 批准号:
7541020 - 财政年份:2008
- 资助金额:
$ 51.58万 - 项目类别:
相似海外基金
Development of education and dissemination methods for psychiatric nurses to introduce complementary and alternative therapies from the physical side
开发精神科护士的教育和传播方法,从身体方面引入补充和替代疗法
- 批准号:
26463484 - 财政年份:2014
- 资助金额:
$ 51.58万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Alternative therapies for antibiotic-resistant Helicobacter pylori infection
抗生素耐药性幽门螺杆菌感染的替代疗法
- 批准号:
23590890 - 财政年份:2011
- 资助金额:
$ 51.58万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Alternative Therapies for Benign Prostate Symptoms
良性前列腺症状的替代疗法
- 批准号:
8147503 - 财政年份:2010
- 资助金额:
$ 51.58万 - 项目类别:
Scientific evaluation of therapeutic effects and mechanism of alternative therapies using PET molecular imaging technique.
利用PET分子成像技术科学评估替代疗法的治疗效果和机制。
- 批准号:
21590754 - 财政年份:2009
- 资助金额:
$ 51.58万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Treating Burn injuries: First-aid and alternative therapies
治疗烧伤:急救和替代疗法
- 批准号:
nhmrc : 409902 - 财政年份:2006
- 资助金额:
$ 51.58万 - 项目类别:
NHMRC Postgraduate Scholarships
PREVENTING COGNITIVE DECLINE WITH ALTERNATIVE THERAPIES
通过替代疗法预防认知能力下降
- 批准号:
7206559 - 财政年份:2005
- 资助金额:
$ 51.58万 - 项目类别:
Alternative Therapies for Alcohol and Drug Abuse
酒精和药物滥用的替代疗法
- 批准号:
6861518 - 财政年份:2004
- 资助金额:
$ 51.58万 - 项目类别:
Alternative Therapies for Alcohol and Drug Abuse
酒精和药物滥用的替代疗法
- 批准号:
6952268 - 财政年份:2004
- 资助金额:
$ 51.58万 - 项目类别:
Alternative Therapies for Alcohol and Drug Abuse
酒精和药物滥用的替代疗法
- 批准号:
7115879 - 财政年份:2004
- 资助金额:
$ 51.58万 - 项目类别:
Alternative Therapies for Alcohol and Drug Abuse
酒精和药物滥用的替代疗法
- 批准号:
7237832 - 财政年份:2004
- 资助金额:
$ 51.58万 - 项目类别: